Researchers at Kansas State University are utilizing a novel approach for the development of an African swine fever virus (ASFv) vaccine. This invention utilizes a combination of an ASFv proteins & DNA plasmids as vaccine formulation, as opposed to traditional approaches under research by other academic and industry groups.
In preliminary studies, pigs were vaccinated with this candidate vaccine. Serum from the pigs was then analyzed for an immune response and also for an ability to neutralize ASFv in virus neutralization assays as a quantitative indication for a possible protective immune response. A robust neutralizing antibody response was detected using specific ASFV protein and plasmid combinations.
This preliminary research needs to be expanded upon, and tested in vaccination/challenge studies. K-State has one of only two facilities in the United States that can conduct BSL-3AG ASFv challenge studies in pigs. We are seeking an industry partner to collaborate on further studies and eventual commercialization.
-Subunit, safe and DIVA-compatible approach to ASFv vaccinology
-K-State’s foreign animal disease expertise & research capabilities
-Provisional patent application filed in December 2015.